Truist Financial’s Matinas BioPharma MTNB Stock Holding History

Truist Financial’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,102	Closed	-$207K	–	2783
2021 Q4	$207K	Hold	4,102	–	–	﹤0.01%	2573
2021 Q3	$267K	Hold	4,102	–	–	﹤0.01%	2417
2021 Q2	$159K	Hold	4,102	–	–	﹤0.01%	2620
2021 Q1	$215K	Buy	+4,102	New	+$275K	﹤0.01%	2464

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Truist Financial's MTNB Position: Q1 2022 in Review

Truist Financial sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 4,102 shares — an estimated $207K sold.

Truist Financial first reported a position in MTNB in Q1 2021 and held it in 4 quarters. The position peaked at $267K in Q3 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

Truist Financial reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
Truist Financial sold 4,102 Matinas BioPharma shares in Q1 2022, an estimated $207K.
Truist Financial first reported a position in Matinas BioPharma in Q1 2021 and held it in 4 quarters.
Truist Financial's Matinas BioPharma position peaked at $267K in Q3 2021.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.